Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

ClinicalTrials.gov ID: NCT07256392

Public ClinicalTrials.gov record NCT07256392. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials. This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.

Study identification

NCT ID
NCT07256392
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
Celldex Therapeutics
Industry
Enrollment
1,370 participants

Conditions and interventions

Interventions

Biological · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 25, 2025 (Actual)
Primary completion
Sep 2028 (Estimated)
Completion
Sep 2028 (Estimated)
Last update posted
Oct 7, 2026

2025 – 2028

United States locations

U.S. sites
43
U.S. states
20
U.S. cities
38
Facility City State ZIP Site status
Cahaba Dermatology & Skin Health Center, LLC Birmingham Alabama 35244 —
Medical Research of Arizona Scottsdale Arizona 85251 —
Center for Dermatology & Plastic Surgery - Avacare Scottsdale Arizona 85260 —
Kern Research Bakersfield California 93301 —
Allergy and Asthma Associates of Southern California - Laguna Niguel - CRN Laguna Niguel California 92677 —
California Allergy and Asthma Medical Group Los Angeles California 90025-7014 —
Dermatology Research Associates Los Angeles California 90045 —
LA Universal Research Center, Inc. Los Angeles California 90057 —
Asthma and Allergy Associates Colorado Springs Colorado 80907 —
Encore Medical Research of Boynton Beach LLC Boynton Beach Florida 33436 —
Dolphin Medical Research Doral Florida 33172 —
Direct Helpers Research Center Hialeah Florida 33012 —
Miami Dade Medical Research Institute, LLC Miami Florida 33176 —
Deluxe Health Center Miami Lakes Florida 33014 —
Sarasota Clinical Research Sarasota Florida 34239 —
GCP, Global Clinical Professionals St. Petersburg Florida 33705 —
Advanced Clinical Research Institute (ACRI) - Florida Tampa Florida 33607 —
Centricity Research Columbus Dermatology Columbus Georgia 31904 —
Endeavor Health Skokie Illinois 60026 —
The South Bend Clinic - Avacare South Bend Indiana 46617 —
Allergy and Asthma Specialists PSC Owensboro Kentucky 42301 —
John Hopkins University Baltimore Maryland 21224 —
DermAssociates, LLC Rockville Maryland 20850 —
Institute for Asthma and Allergy Wheaton Maryland 20902 —
Michigan Center for Research Co., LLC Clarkston Michigan 48346 —
Respiratory Medicine Research Institute of Michigan PLC Ypsilanti Michigan 48197 —
Midwest Clinical Research St Louis Missouri 63141 —
Washington University School of Medicine St Louis Missouri 63141 —
Montana Medical Research, Inc. Missoula Montana 59808 —
Allergy Partners of NJ, PC Ocean City New Jersey 07712 —
Markowitz Medical PLLC dba OptiSkin Medical New York New York 10128 —
Bexley Dermatology Research Bexley Ohio 43209 —
Auni Allergy Findlay Ohio 45840 —
Toledo Institute for Clinical Research Toledo Ohio 43617 —
Toledo Institute of Clinical Research Toledo Ohio 43617 —
Portland Allergy and Asthma Clackamas Oregon 97015 —
Clinical Partners LLC Johnston Rhode Island 02919 —
Alina Clinical Trials LLC Dallas Texas 75225 —
Western Sky Medical Research El Paso Texas 79912 —
Rainey & Finklea San Antonio (RFSA) Dermatology San Antonio Texas 78213 —
Allergy and Asthma Care of Waco Waco Texas 76712 —
Allergy Associates of Utah Sandy City Utah 84093 —
Kalo Clinical Research West Valley City Utah 84120 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 139 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07256392, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 7, 2026 · Synced Oct 30, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07256392 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →